Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

The role of maternal homocysteine concentration in placenta-mediated complications: findings from the Ottawa and Kingston birth cohort

BMC Pregnancy and Childbirth201919:75

https://doi.org/10.1186/s12884-019-2219-5

  • Received: 22 June 2018
  • Accepted: 11 February 2019
  • Published:
Open Peer Review reports

Abstract

Background

Homocysteine is an intermediate metabolite implicated in the risk of placenta-mediated complications, including preeclampsia, placental abruption, fetal growth restriction, and pregnancy loss. Large cohort and case-control studies have reported inconsistent associations between homocysteine and these complications. The purpose of this study was to investigate whether elevated maternal plasma homocysteine concentration in the early to mid-second trimester is associated with an increased risk of placenta-mediated complications. We examined the following potential moderating factors that may explain discrepancies among previous studies: high-risk pregnancy and the MTHFR 677C>T polymorphism.

Methods

We analyzed data from participants recruited to the Ottawa and Kingston (OaK) Birth Cohort from 2002 to 2009 in Ottawa and Kingston, Canada. The primary outcome was a composite of any placenta-mediated complication, defined as a composite of small for gestational age (SGA) infant, preeclampsia, placental abruption, and pregnancy loss. Secondary outcomes were, individually: SGA infant, preeclampsia, placental abruption, and pregnancy loss. We conducted multivariable logistic regression analyses with homocysteine as the primary continuous exposure, adjusting for gestational age at the time of bloodwork and explanatory maternal characteristics. The functional form, i.e., the shape of the homocysteine association with the outcome was examined using restricted cubic splines and information criteria (Akaike’s/Bayesian Information Criterion statistics). Missing data were handled with multiple imputation.

Results

7587 cohort participants were included in the study. Maternal plasma homocysteine concentration was significantly associated (linearly) with an increased risk of both the composite outcome of any placenta-mediated complication (p = 0.0007), SGA (p = 0.0010), severe SGA, and marginally with severe preeclampsia, but not preeclampsia, placental abruption and pregnancy loss. An increase in homocysteine concentration significantly increased the odds of any placenta-mediated complication (odds ratio (OR) for a 5 μmol/L increase: 1.63, 95% Confidence Interval (CI) 1.23–2.16) and SGA (OR 1.76, 95% CI 1.25–2.46). Subgroup analyses indicated some potential for modifying effects of the MTHFR 677C>T genotype and high-risk pregnancy, although the interaction was not statistically significant (high-risk subgroup OR 2.37, 95% CI 1.24–4.53, p-value for interaction =0.14).

Conclusions

Our results suggest an independent effect of early to mid-pregnancy elevated maternal homocysteine on placenta-mediated pregnancy complications.

Keywords

  • Homocysteine
  • Hyperhomocysteinemia
  • Pregnancy complication
  • Placenta
  • Preeclampsia
  • Small for gestational age
  • Placental abruption
  • Pregnancy loss

Background

Maternal plasma homocysteine concentration is proposed to be associated with certain pregnancy complications [1]. Based on evidence supporting the role of homocysteine in endothelial dysfunction and as a risk factor for cardiovascular disease, elevated maternal homocysteine is hypothesized to play a role in placenta-mediated pregnancy complications (PMCs), including preeclampsia, placental abruption, intrauterine growth restriction (IUGR), and pregnancy loss [25]. All have been linked to abnormal placental vasculature, share a common placental pathophysiology, and have an increased risk to reoccur [6, 7].

Within the 1-carbon metabolic cycle, homocysteine is an intermediate metabolite formed in the methionine cycle. Homocysteine can be transmethylated to form methionine, which in turn is converted to S-adenosylmethionine, the main cellular methyl donor from which methyl groups can be transferred to multiple recipient molecules, including DNA and histones. The complex cycle involves key co-enzymes and co-factors including vitamins B9 (folate), B6 and B12. Polymorphisms in genes related to 1-carbon metabolism, as well as various modifiable lifestyle and behavioural factors are associated with elevated homocysteine [8, 9].

Studies have reported inconsistent associations between maternal homocysteine, measured at different time points in pregnancy and placenta-mediated complications [10, 11]; even among larger cohort and case-control studies measuring homocysteine from early pregnancy, the associations are inconsistent [1218]. The discrepancies could be due to moderating factors like high-risk pregnancy and differences in population frequencies of the MTHFR 677C>T polymorphism that can lead to moderately elevated homocysteine [19, 20]. Discrepancies could also arise from different percentile cut-offs used to define elevated homocysteine [13, 14, 21].

The purpose of this study was to investigate whether elevated maternal plasma homocysteine concentration measured in the early to mid-second trimester of pregnancy is associated with an increased risk of PMCs. Our analytic approach sought to explore potential non-linear effects of homocysteine concentration and other continuous factors so as to retain as much information about the association, which can otherwise be lost through categorizing continuous variables [22]. We also sought to determine whether the association is modified by the MTHFR 677C>T genotype and by high-risk pregnancy.

Methods

Study design

Women attending prenatal appointments and planning to deliver at The Ottawa Hospital, the Ottawa region, or the Kingston General Hospital were recruited to the Ottawa and Kingston (OaK) Birth Cohort from 2002 to 2009. Participants were included if between 12 and 20 weeks gestation of a viable singleton or twin pregnancy. For the present study, participants were excluded from the analytic data set if non-singleton, recruited before 12 or after 20 weeks gestation, if they withdrew, were lost to follow-up, or if the pregnancy was terminated.

Details of the cohort study have been previously reported [23]. Briefly, the baseline survey and post-partum follow-up consisted of an interviewer-administered questionnaire and hospital record abstraction. Maternal blood samples were collected at baseline and laboratory personnel were blind to outcomes. Blood samples for homocysteine and MTHFR were collected in K2EDTA Vacutainer tubes (Becton Dickinson, Lincoln Park, NJ) and for serum folate in serum separator tubes (Becton Dickinson). Samples for plasma were immediately placed on ice and within 30 min centrifuged in 4 °C at 3000×g for 10 min, then aliquoted and stored at − 20 °C. Plasma homocysteine (μmol/L) was measured on the Abbott AxSYM II Immunoassay System (Abbott Laboratories, Abbott Park, IL) using fluorescence polarization immunoassay. Blood samples for serum were centrifuged at 3000×g for 10 min, then aliquoted and stored at − 20 °C. Serum folate (nmol/L) was measured using the Beckman Coulter Access 2 and Unicel DxI 800 immunoassay analyzers using manufacturer’s reagents (Beckman Coulter, Brea CA). Homocysteine and folate were measured within one month in batches.

Outcomes

The primary outcome was the composite of placenta-mediated complications (PMCs): small for gestational age (SGA), preeclampsia, placental abruption, and pregnancy loss. The secondary outcomes were individual components of the composite. Additionally we investigated severe SGA <5th percentile and severe preeclampsia.

A small for gestational age infant had a birth weight less than the 10th or 5th percentile of sex and gestational age-adjusted population standards [24]. Pregnancy loss was intrauterine death before 20 weeks or stillbirth. Preeclampsia was new onset hypertension with proteinuria. Hypertension was a diastolic blood pressure reading greater than or equal to 90 mm Hg and proteinuria of 2+ on a dipstick or proteinuria greater than 300 mg in a 24-h urine collection measured on two separate occasions of at least 6 h apart. Preeclampsia with delivery prior to 35 weeks gestation was considered severe [25]. Placental abruption was antepartum bleeding with objective evidence either on ultrasound or inspection of the placenta at birth or a pathologic examination of a retro-placental clot [26]. A committee of medical experts blind to participant exposure status independently examined information abstracted from medical records to adjudicate preeclampsia and placental abruption.

Potential risk factors

Potential confounders, risk factors, and interactions were specified prior to multivariable modeling using knowledge of the subject matter, our analyses of homocysteine determinants in OaK participants (unpublished), and previous work investigating PMCs [1214, 21, 27]. We considered the following factors: maternal age, race, education, income, nulliparity, smoking, diabetes, use of hormonal birth control prior to conception, chronic hypertension, history of PMCs, folic acid supplementation, and serum folate. Gestational age at recruitment was abstracted from hospital records.

Statistical analyses

All statistical analyses were performed in SAS® version 9.4 and RStudio version 0.99.892, R version 3.2.3 [28] and statistical significance was assessed at the 5% level. A variable clustering algorithm was used to examine multicollinearity among independent variables. Missing data patterns were visualized and multiple imputation was performed using multivariate imputation by chained equations [29, 30]. This approach uses sequential regression imputation to create multiple “complete” datasets, a procedure that is flexible and generates multiple predictions for each missing value as a function of all observed data (including auxiliary variables), taking into account the type of variable (i.e., continuous, binary, categorical, ordinal). The number of imputations was set to 10 which is considered an adequate number of imputations [3032].

Regression analyses

We conducted multivariable logistic regression analyses to examine the association of plasma homocysteine concentration (as the primary exposure of interest) with PMCs, while adjusting for the identified potential confounders and risk factors. We did not transform homocysteine because log-transformation did not substantially normalize the distribution (Additional file 1: Figure A). Because serum folate is intermediate with respect to folic acid supplementation, analyses were conducted with and without serum folate to note any changes in effect estimates for folic acid supplementation. Changes were also noted for outliers in homocysteine concentration.

Multivariable model building was conducted as follows [22]. An initial model was fit including main effects for all independent variables. Continuous variables, i.e., homocysteine, gestational age, maternal age, BMI, and serum folate were modeled using restricted cubic splines with five knots set at the 5th, 27.5th, 50th, 72.5th, and 95th quantiles. Next, a plot of partial associations referred to as an ANOVA plot, corrected for the number of degrees of freedom, was generated to visualize strong and weak partial associations. The strengths of association informed a decision of how many degrees of freedom to allocate to each variable: strong associations were modeled with greater complexity than weak associations. For example, weaker partial associations in continuous variables were reduced to fewer knots or a linear term, while categorical and ordinal variables were collapsed. Akaike’s Information Criterion (AIC) and the Bayesian Information Criterion (BIC) were then used to confirm the allocations [22].

The multivariable logistic regression models were fit using the rms (regression modelling strategies) package [33]. Odds Ratios for continuous variables modelled with restricted cubic splines were estimated comparing the 75th to 25th percentile. The logistic regression model was fit to each imputed dataset and results were combined across the 10 datasets using Rubin’s method which computes imputation-adjusted variances and average betas [30, 34]. Analyses of outcomes with a low frequency of events were conducted using penalized maximum likelihood. The best penalty factor was identified by tracing effective AIC for different penalties [22, 33].

Subgroup analyses

Subgroup analyses examined the modifying effect of the MTHFR 677C>T genotype and high-risk pregnancy, defined as chronic hypertension, diabetes, history of a PMC, or BMI greater than 35. This was done by including interaction terms with homocysteine and each potential moderator. Subgroup analyses were not conducted for placental abruption and pregnancy loss due to a low number of events.

Results

Of the 8085 women recruited to the OaK Birth Cohort, 7587 were included in our study (Fig. 1). Descriptive characteristics of participants are presented in Table 1. Maternal education and household income were highly correlated; income was dropped from multivariable analyses because education was more strongly associated with the outcomes. ANOVA plots of partial associations revealed relatively strong associations between homocysteine and the outcomes any placenta-mediated complication (PMC) and SGA (Additional file 2). Nevertheless, AIC and BIC values confirmed that for each outcome the models with homocysteine specified as a simple linear term provided the best fit to the data. The final models included both serum folate and folic acid supplementation because excluding folate did not substantially change effect estimates for folic acid supplementation. We identified two outliers with homocysteine > 20 μmol/L that were included in the final models because exclusion yielded similar results (data not shown).
Fig. 1
Fig. 1

Participant flow diagram for the analytic dataset

Table 1

Participant characteristics

Variable

Frequency

n = 7587

Age

 Mean (SD)

30.3 (5.06)

Race a (missing/unknown N = 415, 5.5%)

 African

152

(2.12%)

 Middle eastern

224

(3.12%)

 Asian

422

(5.88%)

 Caucasian

6250

(87.1%)

 Other

124

(1.73%)

BMI (missing N = 136, 1.8%)

 Mean (SD)

24.9 (5.5)

 Range

14.7–61.3

Participant education (missing N = 7, 0.09%)

 Grade school

153

(2.02%)

 High school

962

(12.7%)

 College/University not completed

754

(10.0%)

 College/University completed

5711

(75.3%)

Paternal/partner education (missing N = 95, 1.25%)

 Grade school

137

(1.83%)

 High school

1519

(20.3%)

 College/University not completed

590

(7.88%)

 College/University completed

5246

(70.0%)

Household income (missing N = 485, 6.4%)

  < 25 k

415

(5.84%)

 25 k - < 50 k

1188

(16.7%)

 50 k - < 80 k

2077

(29.2%)

  > =80 k

3422

(48.2%)

MTHFR genotype b

 CC (wild type)

1768

(44.1%)

 CT (heterozygous)

1760

(43.9%)

 TT (mutant)

478

(11.9%)

aRace was categorized similar to the U.S. Census, in which the categories are: White, Black or African American, American Indian or Alaska Native, Asian (Far-east and Indian subcontinent), and Hawaiian or Pacific Islander. Participants whose response suggested a Central/South American, Latino, Hispanic, or Aboriginal background were classified into the ‘Other’ category. This follows the U.S. Census Bureau’s classification that: “People who identify their origin as Hispanic, Latino, or Spanish may be of any race” [51]

bMeasured in a subset of participants (n = 4006)

Effect of homocysteine

Homocysteine concentration was significantly higher in participants with the composite outcome of any PMC, small for gestational age (SGA) infants, and pregnancy loss (Additional file 1: Table A), also demonstrated visually by boxplots of the homocysteine distribution according to pregnancy outcome (Additional file 1: Figure A). In adjusted analyses, higher plasma homocysteine concentration was significantly associated with increased odds of any PMC (Table 2, p = 0.0007), SGA (Table 3, p = 0.0010), was marginally associated with preeclampsia (p = 0.07), and was not associated with placental abruption, and pregnancy loss (Table 3, 0.99, and 0.16). Additionally, homocysteine was associated with severe SGA (<5th percentile) and marginally with severe preeclampsia (delivery < 35 weeks gestation) (Table 3, 0.0012, and 0.0595). A 5 μmol/L change in homocysteine concentration, which is approximately 4 SDs of the homocysteine concentration, was associated with a 63% increased odds of any PMC (Odds Ratio (OR) 1.63, 95% Confidence Interval (CI) 1.23–2.16) and a 76% increased odds of SGA (OR 1.76, 95% CI 1.25–2.46). Serum folate and folic acid supplementation were not associated with the outcomes (Table 2 and Additional file 3: Tables C.1-C.4).
Table 2

Multivariable logistic regression analysis of the association between homocysteine and any placenta-mediated complication a (759 events b), n = 7587

Variable

Odds ratio (95% CI)

p-value c

Homocysteine (linear)

  

0.0007

 5 μmol/L increase

1.629

(1.227, 2.161)

 

Age (restricted cubic spline, three knots)

  

0.0031

 34 versus 27 years

1.187

(1.063, 1.325)

 

Race

  

0.0002

 Caucasian versus others

0.644

(0.509, 0.814)

 

Education

  

0.0056

 College/University completed versus less than completed

0.763

(0.630, 0.924)

 

Nulliparous

  

< 0.0001

 Yes versus no

1.941

(1.636, 2.303)

 

Smoking

  

< 0.0001

 No

Reference

  

 Second-hand

0705

(0.392, 1.268)

 

 Med/light smoker (< 10 cigarettes per day)

1.631

(1.228, 2.166)

 

 Heavy smoker (> 10 cigarettes per day)

1.921

(1.348, 2.737)

 

Diabetes

  

0.0336

 Yes versus no

1.687

(1.041, 2.733)

 

BMI (restricted cubic spline, four knots)

  

0.0499

 27.3 versus 21.1 kg/m2

1.057

(0.883, 1.265)

 

Hormonal birth control prior to conception

  

0.3692

 No

Reference

  

 Oral

0.927

(0.784, 1.096)

 

 Injection or IUD

0.732

(0.436, 1.227)

 

Chronic hypertension

  

< 0.0001

 Yes versus no

2.750

(1.687, 4.483)

 

History of PMC (Preeclampsia, placental abruption, IUGR, stillbirth, loss)

  

0.0110

 Yes versus no

1.359

(1.073, 1.722)

 

Folic acid supplementation

  

0.7328

 Yes versus no supplementation

0.943

(0.674, 1.320)

 

Serum folate (linear)

  

0.5326

 45.1 versus 30.6 nmol/L

1.025

(0.949, 1.106)

 

Gestational age at blood work (restricted cubic spline, four knots)

  

0.0004

 13.7 versus 12.4 weeks

0.939

(0.804, 1.095)

 

aAny placenta-mediated complication- composite of small for gestational age (SGA) <10th percentile, preeclampsia, placental abruption, and pregnancy loss

b79 missing outcome values imputed

cWald test of most meaningful hypotheses, pooled across multiple imputation datasets

Table 3

Summary of multivariable logistic regression analyses of the association between homocysteine and placenta-mediated complications, n = 7587 a

Outcome variable

Odds ratio (95% CI) b

p-value c

Any placenta-mediated complication (759 events d)

 Homocysteine (linear)

  

0.0007

  5 μmol/L increase

1.629

(1.227, 2.161)

 

SGA (512 events d)

 Homocysteine (linear)

  

0.0010

  5 μmol/L increase

1.756

(1.254, 2.458)

 

SGA < 5th percentile (221 events d)

 Homocysteine (linear)

  

0.0012

  5 μmol/L increase

2.022

(1.322, 3.092)

 

Preeclampsia (227 events)

 Homocysteine (linear)

  

0.0736

  5 μmol/L increase

1.546

(0.959, 2.491)

 

Severe preeclampsia (43 events)

 Homocysteine (linear)

  

0.0595

  5 μmol/L increase

1.762

(0.978, 3.177)

 

Placental abruption (68 events)

 Homocysteine (linear)

  

0.9851

  5 μmol/L increase

1.005

(0.590, 1.711)

 

Pregnancy loss (85 events)

 Homocysteine (linear)

  

0.1586

  5 μmol/L increase

1.392

(0.879, 2.206)

 

aComplete results reported in Table 2: any placenta-mediated complication, Additional file 4, and Additional file 3: Table C.1: SGA, Table C.2: Preeclampsia, Table C.3: Placental abruption, and Table C.4: Pregnancy loss

bModels adjusted for maternal age, race, education, parity, smoking, diabetes, BMI, hormonal birth control prior to conception, chronic hypertension, history of a placenta mediated complication, folic acid supplementation, serum folate, and gestational age at blood work

cWald test of most meaningful hypotheses, pooled across multiple imputation datasets

d79 Missing outcome values imputed

Subgroup analyses

The results of the subgroup analyses are presented in Tables 4 and 5. In the subset of 4006 OaK participants with measured genotype, the interaction between MTHFR 677C>T and homocysteine was not statistically significant for preeclampsia (p = 0.84) but there was some evidence of interaction for any PMC (p = 0.12) and for SGA (p = 0.07) with associations qualitatively different within each subgroup. Associations in the CC/CT subgroups were positive and significant, whereas in TT subgroup associations were negative and not significant, with wide confidence intervals. Figure 2 illustrates these trajectories for the composite outcome with homocysteine. The interaction between high-risk pregnancy and homocysteine was not statistically significant for any PMC and SGA (p = 0.27 and p = 0.51 respectively), but there was some evidence of a moderating effect for preeclampsia (p = 0.14, Table 5). While the interaction effect (and hence, the difference in association between the high and low-risk subgroups) was not statistically significant at the conventional 5% level, the odds ratio was higher and statistically significant in the high-risk group (OR 2.84, 95% CI 1.19 to 6.79 for a 5 μmol/L change in homocysteine concentration) compared to a lower and non-statistically significant OR in the low-risk group (OR 1.31, 95% CI 0.74 to 2.30).
Table 4

Multivariable logistic regression analyses examining the moderating effect of MTHFR 677C>T genotype a on the association between homocysteine and placenta-mediated complications, n = 4006

Outcome variable

Odds ratio (95% CI) for 5 μmol/L increase b

p-value c

TT

CC/CT

Any placenta-mediated complication (395 events d)

0.712 (0.243, 2.083)

1.778 (1.159, 2.729)

0.1172

SGA (277 events d)

0.639 (0.161, 2.536)

2.430 (1.450, 4.073)

0.0714

Preeclampsia (109 events)

1.174 (0.523, 2.633)

1.258 (0.682, 2.322)

0.8439

aHomocysteine*MTHFR 677C>T genotype (Factor + higher order factors)

bModel adjusted for maternal age, race, education, parity, smoking, diabetes, BMI, hormonal birth control, chronic hypertension, history of PMC, folic acid supplementation, serum folate, gestational age at blood work

cWald test of most meaningful hypotheses, pooled across multiple imputation datasets

d40 Missing outcome values imputed

Table 5

Multivariable logistic regression analyses examining the moderating effect of high-risk pregnancy a on the association between homocysteine and placenta-mediated complications, n = 7587

Outcome variable

Odds ratio (95% CI) for 5 μmol/L increase b

p-value c

High-risk

Low-risk

Any placenta-mediated complication (759 events d)

2.368 (1.239, 4.525)

1.595 (1.176, 2.163)

0.2714

SGA (512 events d)

2.474 (1.050, 5.828)

1.821 (1.276, 2.597)

0.5081

Preeclampsia (227 events)

2.839 (1.187, 6.792)

1.308 (0.743, 2.302)

0.1351

aHomocysteine*High-risk pregnancy (Factor + higher order factors)

bModel adjusted for maternal age, race, education, parity, smoking, hormonal birth control, folic acid supplementation, serum folate, gestational age at blood work

cWald test of most meaningful hypotheses, pooled across multiple imputation datasets

d79 Missing outcome values imputed

Fig. 2
Fig. 2

Modelled association between plasma homocysteine (linear) and any placenta-mediated complication, by MTHFR 677C>T genotype CC/CT (wild type and heterozygous) and TT (mutant). Shaded area represents 95% CI

Effects of other factors

Different groups of risk factors were associated with SGA and preeclampsia (Tables 3, C.1-C.2). A high school or incomplete post-secondary education and smoking were associated with increased odds for any PMC and SGA. Chronic hypertension, diabetes, and history of experiencing a PMC were associated with increased odds for any PMC and preeclampsia.

Discussion

Main findings

We analyzed data from 7587 participants from the Ottawa and Kingston (OaK) Birth cohort. We found that maternal homocysteine concentration in the early to mid-second trimester was associated with increased odds of any placenta-mediated complication (PMC): a composite of small for gestational age (SGA), preeclampsia, placental abruption, and pregnancy loss, and was associated with increased odds of SGA and severe SGA and preeclampsia. In the high-risk subgroup homocysteine was associated with increased odds of preeclampsia.

Strengths and limitations

To our knowledge, this is the largest cohort study to investigate the association between early to mid-second trimester maternal homocysteine concentration and the risk of placenta-mediated complications. We used multiple imputation to deal with missing values and conducted rigorous multivariable logistic regression analyses designed to explore flexible functional forms of association with homocysteine and other continuous factors, controlling for a wide range of potential confounders.

In most larger studies, homocysteine was dichotomized or grouped to investigate non-linearity and a threshold effect [12, 16]. However, the Hordaland Homocysteine study of several thousand participants suggested that for most conditions including pregnancy complications and adverse pregnancy outcomes, homocysteine exhibits a continuous concentration-response relation [1, 27]. Thus, one of the main strengths of our study is that we accounted for the functional form, i.e., shape of the association, of homocysteine and other continuous variables in relation to the outcomes of interest, which to the best of our knowledge has not been previously reported.

One of the main limitations of our study is that we did not examine the effect of Vitamins B6 and B12. In a survey of the Canadian population from 2007 to 2009, Vitamin B12 was the main determinant of elevated homocysteine concentration in the folate replete [35]. We would expect OaK participants to have adequate Vitamin B12 levels because 85% were supplementing with multivitamin or prenatal vitamin supplements, which likely contained Vitamin B12. Caffeine or coffee consumption is another homocysteine determinant we did not examine [9], though pregnant women tend to consume less caffeine during pregnancy.

Interpretation

Other studies have reported an increased risk of SGA associated with elevated homocysteine [12, 36]. In Bergen et al.’s cohort of 5085 participants recruited in the Netherlands from 2002 to 2006, early second trimester homocysteine in the upper versus lower quintile was associated with an increased risk of SGA (<5th centile) [12]. In Dodds et al.’s cohort of 2119 participants recruited in Nova Scotia, Canada from 2002 to 2005, a study time frame similar to our OaK birth cohort, a homocysteine concentration greater than the 90th percentile was not associated with a risk of SGA [13]. The mean homocysteine concentration in the latter study was lower than Bergen et al. [12], but comparable to our participants’ mean homocysteine concentration of 4.8 μmol/L. In another study of 65 SGA cases and 358 controls recruited in a Chinese textile factory from 1996 to 1998, pre-conception homocysteine above the 90th percentile was not associated with an increased risk of SGA [16].These latter two studies dichotomized homocysteine concentration using cut-offs that are not necessarily physiological, which may limit comparability with our findings and those of Bergen et al. [12]

The MTHFR 677C>T genotype qualitatively modified the association of homocysteine with any PMC and SGA. However uncertainty around the negative effect of the TT genotype, likely due to fewer participants the TT subgroup, makes it difficult to interpret the modifying effect. Higher folate intake and status are known to mitigate but not eliminate the effect of this polymorphism on homocysteine concentration [19, 37, 38]. Although approximately 95% of our sample was consuming a folic acid supplement and white flour and other cereal products in Canada have been fortified with folic acid since the late 1990s, homocysteine concentration was associated with the MTHFR genotype in the OaK cohort. Given the variations in clinical testing for MTHFR genotype in current obstetric practice [39], our study findings suggest testing may be warranted, particularly in high-risk subgroups, for example, those who exhibit comorbidities or a history of complications.

We found that elevated homocysteine was marginally associated with an increased risk of preeclampsia, and that the association was significant in the high-risk subgroup. Others have found no association [12, 14]; for example, Kahn et al.’s nested case-control study with 113 preeclampsia cases and 443 controls recruited in Montreal from 1999 to 2004 [14]. Studies of repeated homocysteine measurement during pregnancy have reported increasing homocysteine concentration during the course of preeclampsia [40]. In a longitudinal analysis of 252 women of whom 49 developed preeclampsia, homocysteine increased in the preeclampsia group independent of B-vitamin (B6, B12, and folate) and obesity status, while concentrations in the uncomplicated group remained steady [41]. Therefore early homocysteine measurement, as in our study, may pre-date onset of disease and changes in homocysteine. Our finding of a stronger association of homocysteine in severe preeclampsia, marginally significant with fewer outcome events, also suggests a role of homocysteine earlier in pregnancy when severity is increased.

Some studies have, however, reported an increased risk of preeclampsia associated with higher homocysteine concentrations [13, 4245]. Many of these studies were conducted during a time period before routine peri-conceptional folic acid supplementation and/or mandatory folic acid fortification (i.e., the early to mid-1990s) [4244], or were conducted in countries without mandatory folic acid fortification [4547]. This suggests that where folate intake is lower, homocysteine levels would tend to be higher and therefore homocysteine might play a greater role, earlier on, in the development of preeclampsia.

We report the association of the range of potential confounders with the composite and individual outcomes. Our results, although exploratory in this regard, demonstrated a greater role of diabetes and chronic hypertension in the development of preeclampsia compared to SGA. In a clinical opinion paper, Ness and Sibai [48] hypothesized that the maternal syndrome observed in preeclampsia develops in the presence of abnormal placentation that interacts with maternal metabolic syndrome, and that fetal growth restriction develops in the absence of metabolic syndrome. Our findings of increased odds of preeclampsia in the high-risk subgroup also lend support to this hypothesized role of developing endothelial dysfunction in preeclampsia.

In our study elevated homocysteine concentration was not associated with an increased risk of placental abruption and pregnancy loss, but a greater number of events would be necessary to confirm an association. Some studies have found no association of homocysteine with early pregnancy loss [15, 17, 49]. However, one-time early pregnancy losses are characteristically different from recurrent early pregnancy losses and losses throughout pregnancy [10].

Conclusions

In summary, our results support an independent effect of early to mid-pregnancy elevated homocysteine on placenta-mediated pregnancy complications. Our findings are comparable with similar large studies; high-risk pregnancy and potentially the MTHFR 677C>T genotype may contribute to some of the observed differences between studies. As with ongoing investigations into the role of homocysteine in cardiovascular disease, large Mendelian randomization studies could further confirm the etiological role of homocysteine in placenta-mediated pregnancy complications [50].

Abbreviations

AIC: 

Akaike’s information criterion

BIC: 

Bayesian information criterion

BMI: 

Body mass index

IUGR : 

Intrauterine growth restriction

MTHFR: 

Methylenetetrahydrofolate reductase

OaK: 

Ottawa and Kingston

PMC: 

Placenta-mediated complication

SGA: 

Small for gestational age

Declarations

Acknowledgements

S. H. Chaudhry is a recipient of a PhD Scholarship from the CIHR-Quebec Training Network in Perinatal Research (QTNPR).

Funding

This study was supported by grants from the Canadian Institutes of Health Research (Grant MOP 53188 and 82802, Grant FDN 148438). The funding agency had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SW, MW, RRW, GS, and MR are lead investigators of the Ottawa and Kingston (OaK) Birth Cohort. SC, SW, and MT designed the study. SC analyzed the patient data and wrote the draft manuscript. SC, SW, MT, and AM were involved in interpretation of the data. LG, MW, RRW, GS, and MR critically revised the manuscript and contributed to the final version. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethics approval for the Ottawa and Kingston (OaK) Birth Cohort was obtained from the Ottawa Health Science Network Research Ethics Board (protocol 2002343-01H and 2007034-01H). Eligible participants provided written informed consent. Ethics approval for this secondary analysis was obtained from the OHSN-REB (20160163-01H) on 31 May 2016.

Consent for publication

‘Not applicable’.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
(2)
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada
(3)
Nutrition Research Division, Health Canada, Ottawa, Ontario, Canada
(4)
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
(5)
Department of Obstetrics & Gynaecology, Division of Maternal-Fetal Medicine, Queen’s University, Kington, Ontario, Canada
(6)
Kingston General Hospital Research Institute, Kington, Ontario, Canada

References

  1. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland homocysteine study. Am J Clin Nutr. 2000;71(4):962–8.PubMedView ArticleGoogle Scholar
  2. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–28.PubMedPubMed CentralGoogle Scholar
  3. McCully KS. Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr. 2007;86:1563–8.View ArticleGoogle Scholar
  4. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis. PLoS One. 2011;6(2):e16473.PubMedPubMed CentralView ArticleGoogle Scholar
  5. Wald DS, Bestwick JP, Wald NJ. Homocysteine as a cause of ischemic heart disease: the door remains open. Clin Chem. 2012;58(10):1488–90.PubMedView ArticleGoogle Scholar
  6. Ananth CV, Peltier MR, Chavez MR, Kirby RS, Getahun D, Vintzileos AM. Recurrence of ischemic placental disease. Obstet Gynecol. 2007;110(1):128–33.PubMedView ArticleGoogle Scholar
  7. Ananth CV. Ischemic placental disease: a unifying concept for preeclampsia, intrauterine growth restriction, and placental abruption. Semin Perinatol. 2014;38(3):131–2.PubMedView ArticleGoogle Scholar
  8. Jacques PF, Bostom AG, Wilson PWF, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham offspring cohort. Am J Clin Nutr. 2001;73(3):613–21.PubMedView ArticleGoogle Scholar
  9. Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland homocysteine study. Am J Clin Nutr. 1998;67(2):263–70.PubMedView ArticleGoogle Scholar
  10. Ray JG, Laskin CA. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta. 1999;20(7):519–29.PubMedView ArticleGoogle Scholar
  11. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS. Mapping the theories of preeclampsia: the role of homocysteine. Obstet Gynecol. 2005;105(2):411–25.PubMedView ArticleGoogle Scholar
  12. Bergen NE, Jaddoe VWV, Timmermans S, Hofman A, Lindemans J, Russcher H, et al. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the generation R study. BJOG. 2012;119(6):739–51.PubMedView ArticleGoogle Scholar
  13. Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, Nassar BA, et al. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem. 2008;54(2):326–34.PubMedView ArticleGoogle Scholar
  14. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal preeclampsia study. Am J Obstet Gynecol. 2009;200(2):151.e1–9.View ArticleGoogle Scholar
  15. Ronnenberg AG, Venners SA, Xu X, Chen C, Wang L, Guang W, et al. Preconception B-vitamin and homocysteine status, conception, and early pregnancy loss. Am J Epidemiol. 2007;166(3):304–12.PubMedView ArticleGoogle Scholar
  16. Ronnenberg AG, Goldman MB, Chen D, Aitken IW, Willett WC, Selhub J, et al. Preconception homocysteine and B vitamin status and birth outcomes in Chinese women. Am J Clin Nutr. 2002;76(6):1385–91.PubMedView ArticleGoogle Scholar
  17. Ronnenberg AG, Goldman MB, Chen D, Aitken IW, Willett WC, Selhub J, et al. Preconception folate and vitamin B (6) status and clinical spontaneous abortion in Chinese women. Obstet Gynecol. 2002;100(1):107–13.PubMedGoogle Scholar
  18. Maged AM, Saad H, Meshaal H, Salah E, Abdelaziz S, Omran E, et al. Maternal serum homocysteine and uterine artery Doppler as predictors of preeclampsia and poor placentation. Arch Gynecol Obstet. 2017;296(3):475–82.PubMedView ArticleGoogle Scholar
  19. Clarke R, Bennett DA, Parish S, Verhoef P, Dötsch-Klerk M, Lathrop M, et al. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med. 2012;9(2):e1001177.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Sibani S, Leclerc D, Weisberg IS, O’Ferrall E, Watkins D, Artigas C, et al. Characterization of mutations in severe methylenetetrahydrofolate reductase deficiency reveals an FAD-responsive mutation. Hum Mutat. 2003;21:509–20.PubMedView ArticleGoogle Scholar
  21. Wen SW, Chen X-K, Rodger M, White RR, Yang Q, Smith GN, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol. 2008;198(1):45.e1–7.View ArticleGoogle Scholar
  22. Harrell FE. Regression modeling strategies with applications to linear models, logistic and ordinal regression, and survival analysis. Second Edi Springer Series in Statistics; 2015.Google Scholar
  23. Walker MC, Finkelstein SA, Rennicks White R, Shachkina S, Smith GN, Wen SW, et al. The Ottawa and Kingston (OaK) birth cohort: development and achievements. J Obstet Gynaecol Canada. 2011;33(11):1124–33.View ArticleGoogle Scholar
  24. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A. A New and Improved population-based birth weight for gestational age. Pediatrics. 2001;108(2):e35.PubMedView ArticleGoogle Scholar
  25. Turner JA. Diagnosis and management of pre-eclampsia: an update. Int J Women's Health. 2010;2(1):327–37.View ArticleGoogle Scholar
  26. Macdonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDF, Clark SL, et al. Williams obstetrics. Cunningham FG, Williams JW, editors. Appleton & Lange; 1997. viii, 1448:ill.Google Scholar
  27. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland homocysteine study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136:1731S–40S.PubMedView ArticleGoogle Scholar
  28. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2016. Available from: https://www.r-project.org/ Google Scholar
  29. Templ M, Alfons A, Kowarik A, Prantner B. VIM: Visualization and Imputation of Missing Values. 2016, R package version 4.5.0. Available from: https://cran.r-project.org/package=VIM Google Scholar
  30. van Buuren S, Groothuis-oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.View ArticleGoogle Scholar
  31. Rubin DB. Multiple imputation for survey non-response. New York: Wiley; 1987.View ArticleGoogle Scholar
  32. Von Hippel PT. How many imputations are needed? A comment on Hershberger and fisher (2003). Struct Equ Model. 2005;12(2):334–5.View ArticleGoogle Scholar
  33. Frank E Harrell Jr. rms: Regression Modeling Strategies. 2016, R package version 4.5–0. Available from: https://cran.r-project.org/package=rms Google Scholar
  34. Frank E Harrell Jr, With contributions from Charles Dupont and many others. Hmisc: Harrell Miscellaneous. 2016, R package version 3.17–4. Available from: https://cran.r-project.org/package=Hmisc Google Scholar
  35. MacFarlane AJ, Greene-finestone LS, Shi Y. Vitamin B-12 and homocysteine status in a folate-replete population: results from the Canadian health measures survey. Am J Clin Nutr. 2011;94:1079–87.PubMedView ArticleGoogle Scholar
  36. Furness D, Fenech M, Dekker G, Khong TY, Roberts C, Hague W. Folate, vitamin B12, vitamin B6 and homocysteine: impact on pregnancy outcome. Matern Child Nutr. 2011;9(2):155–66.PubMedView ArticleGoogle Scholar
  37. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet. 2011;378:584–94.PubMedPubMed CentralView ArticleGoogle Scholar
  38. Crider KS, Zhu J, Hao L, Yang Q, Yang TP, Gindler J, et al. MTHFR 677C> T genotype is associated with folate and homocysteine concentrations in a large , population-based , double-blind trial of folic. Am J Clin Nutr. 2011;93(6):1365–72.PubMedView ArticleGoogle Scholar
  39. Long S, Goldblatt J. MTHFR genetic testing: controversy and clinical implications. Aust Fam Physician. 2016;45(4):237–40.PubMedGoogle Scholar
  40. Roes EM, Hendriks JCM, Raijmakers MTM, Steegers-Theunissen RPM, Groenen P, Peters WHM, et al. A longitudinal study of antioxidant status during uncomplicated and hypertensive pregnancies. Acta Obstet Gynecol Scand. 2006;85(2):148–55.PubMedView ArticleGoogle Scholar
  41. Lopez-Alarcon MI, Montalvo-Velarde I, Vital-Reyes VS, Hinojosa-Cruz JC, Leanos-Miranda A, Martinez-Basila A. Serial determinations of asymmetric dimethylarginine and homocysteine during pregnancy to predict pre-eclampsia: a longitudinal study. BJOG. 2015;122(12):1586–92.PubMedView ArticleGoogle Scholar
  42. Sorensen TK, Malinow MR, Williams MA, King IB, Luthy DA. Elevated second-trimester serum homocyst(e)ine levels and subsequent risk of preeclampsia. Gynecol Obstet Investig. 1999;48(2):98–103.View ArticleGoogle Scholar
  43. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol. 2001;185(4):781–5.PubMedView ArticleGoogle Scholar
  44. Cotter AM, Molloy AM, Scott JM, Daly SF. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of nonsevere preeclampsia. Am J Obstet Gynecol. 2003;189(2):391–6.PubMedView ArticleGoogle Scholar
  45. Cheng P-J, Huang S-Y, Su S-Y, Hsiao C-H, Peng H-H, Duan T. Prognostic value of cardiovascular disease risk factors measured in the first-trimester on the severity of preeclampsia. Medicine (Baltimore). 2016;95(5):e2653.View ArticleGoogle Scholar
  46. Onalan R, Onalan G, Gunenc Z, Karabulut E. Combining 2nd-trimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol Obstet Investig. 2006;61:142–8.Google Scholar
  47. Wadhwani NS, Patil VV, Mehendale SS, Wagh GN, Gupte SA, Joshi SR. Increased homocysteine levels exist in women with preeclampsia from early pregnancy. J Matern Fetal Neonatal Med. 2016;29:2719–25.PubMedGoogle Scholar
  48. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol. 2006;195(1):40–9.PubMedView ArticleGoogle Scholar
  49. Hoffman ML, Scoccia B, Kurczynski TW, Shulman LP, Gao W. Abnormal folate metabolism as a risk factor for first-trimester spontaneous abortion. J Reprod Med. 2008;53(3):207–12.PubMedGoogle Scholar
  50. Chen Z, Chen J, Collins R, Guo Y, Peto R, Wu F, et al. China Kadoorie biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol. 2011;40:1652–66.PubMedPubMed CentralView ArticleGoogle Scholar
  51. United States Census Bureau. [cited 2016 Jul 2]. Available from: http://www.census.gov/topics/population/race/about.html

Copyright

© The Author(s). 2019

Advertisement